When a new SmPC or USPI is approved, the standard for everything the company says about the medicine moves on that date. Claims, references, promotional pieces, medical information letters, training decks, risk materials and websites that rely on the changed sections all have to follow. They sit with different teams, in different systems and in different markets, so they move at different speeds. Doctors also ask AI assistants about medicines now, and an assistant answers from whatever it has read, which can include the old label and old web pages.
This guide is for labeling, regulatory, medical information, promotional review and brand teams. It covers where the public record shows exactly what changed in the US, the EU and the UK, the rules that make the timing matter, a checklist of ten places to look, who usually owns each one, and a workable timeline. Every external fact links to its source.
Start by pinning down exactly what changed
Before anyone searches a claims library, write down every changed section with the old and new text side by side, the version or revision date of each label, and the date the change was approved. Every later step depends on this list being complete, and each region publishes the record in a different place.
United States: Highlights, DailyMed and FDA's safety labeling database
A USPI in the current format opens with Highlights, and Highlights carries a list headed Recent major changes. Under 21 CFR 201.57(a)(5), that list names each section of the full prescribing information with a substantive change approved by FDA, with the section number and the month and year the change entered the labeling. A changed section must stay listed for at least one year. In the full prescribing information, the new or modified text in those sections is marked with a vertical line on its left edge (21 CFR 201.57(d)(9)), and the date of the most recent revision sits at the end of Highlights (21 CFR 201.57(a)(15)).
The list has a limit that catches teams out. It covers five sections only: Boxed warning, Indications and usage, Dosage and administration, Contraindications, and Warnings and precautions. A change to Adverse reactions, Drug interactions, Use in specific populations or Clinical studies will not appear there, even though claims and medical information letters often cite exactly those sections.
Two public sources close the gap. FDA's Drug Safety-related Labeling Changes database holds approved safety-related labeling changes from January 2016 onward for NDAs and CDER-regulated BLAs, and it can be searched by section, including Adverse reactions, Drug interactions and Use in specific populations. The National Library of Medicine's DailyMed Labeling Archives retrieve the label that was current on a given date, so you can set the version your content was approved against next to today's. For teams that work programmatically, DailyMed's web services return the version history for a label's set ID and let you download older versions.
European Union: the EPAR and its procedural steps document
For a centrally authorised medicine, EMA publishes a European public assessment report, or EPAR, and keeps the medicine's documents current as it changes: the product information (which holds the SmPC and the package leaflet), the procedural steps document, the medicine overview and, where applicable, the risk management plan. EMA's publication schedule says updated product information appears two weeks after the European Commission decision for an extension of indication, and for other variations two weeks after the decision or four to five weeks after the scientific opinion or notification. For changes to contraindications, or changes that significantly alter how the medicine is used, EMA publishes a summary of opinion on the Friday after the meeting of its medicines committee, the CHMP.
The document that shows what changed is titled Procedural steps taken and scientific information after the authorisation. It is a table with one row per procedure: the application number and scope, the date of the opinion or notification, the date of the Commission decision, which parts of the product information were affected, and a short summary (example). Read the rows dated after your content was last approved and note each procedure that touched the SmPC. For older medicines, the document itself notes that a separate archive version may hold the earlier history, in the EPAR's assessment history section.
The procedural steps table tells you which procedures changed which annexes. For the wording, compare the current SmPC with the version your content was approved against. For a medicine authorised nationally rather than through EMA, the national agency's record plays the same role.
United Kingdom: the emc
UK SmPCs and patient leaflets are published on the emc. When a company updates an SmPC there, the product page carries a View changes link to the document history. For an SmPC it shows which sections changed with a detailed description of each change, and for a leaflet it shows which sections changed. You need to be registered and logged in to an emc account to see it (emc support). The emc's Latest medicines updates page lists recent changes, with a Changes history link for each product.
The emc is only as current as the company keeps it. In the UK case discussed below, the revised SPC was sent to the emc more than three weeks after the change was communicated for implementation, and the Panel noted that the UK company "was, and remained, responsible for updating the eMC."
Why the timing matters
In the EU, Article 87(2) of Directive 2001/83/EC requires that all parts of the advertising of a medicinal product comply with the particulars listed in the SmPC. The UK carries the same rule in regulation 280 of the Human Medicines Regulations 2012. When the SmPC changes, the standard each promotional piece is measured against changes with it, and that includes pieces approved years ago that are still in use.
In the US, labeling that gives prescribers information for use must match the approved labeling. The parts that give that information must be "the same in language and emphasis as labeling approved," and the other parts must be "consistent with and not contrary to" it (21 CFR 201.100(d)(1)). Each promotional piece is submitted to FDA at first use with Form FDA 2253, and the submission must include "a copy of the product's current professional labeling" (21 CFR 314.81(b)(3)(i)), so every revised piece goes in alongside the new label.
What a slow update looks like on the public record
UK Code of Practice cases AUTH/3041/6/18 and AUTH/3042/6/18 (PMCPA case report) followed one SPC update that added a new contraindication. The case report gives the sequence.
| Date | What happened |
|---|---|
| 15 September 2016 | The CHMP issued a positive opinion recommending the SPC update |
| 9 January 2017 | The update was communicated to the companies, the date they treated as formal approval for implementation |
| 3 February 2017 | The revised SPC was sent to the emc |
| 1 March 2017 | New promotional material with the revised prescribing information was issued |
| 29 March 2017 | Older promotional material was withdrawn "as a routine withdrawal," 79 days after formal approval |
| June 2018 | Risk minimisation educational material still lacked the contraindication and had not been submitted to the MHRA |
The Panel was concerned that the older material was withdrawn as a routine withdrawal "rather than to ensure compliance with the Code after the SPC update," and it ruled that material in use until then, with prescribing information that omitted the new contraindication, was not up to date and breached the Code.
The Panel also found that educational material required under the medicine's risk minimisation plan "had still not been updated and submitted to the MHRA for approval" when the company responded to the complaint in June 2018. It ruled a breach for each of seven promotional materials related to a European website "that did not contain the latest version of the prescribing information"; the website had not been launched in the UK, but UK health professionals could reach it. The Panel was also concerned that the company's procedures allowed up to six months to update promotional material for a standard SPC change and 10 business days for an urgent safety update, and it queried whether six months was appropriate.
The Appeal Board publicly reprimanded both companies "for the failures to implement SPC changes and update impacted materials in a timely manner which had potential to impact patient safety," and required audits of their procedures. The complaint arrived in June 2018 and the case was completed in March 2022. Each failure sat somewhere ordinary: a withdrawal schedule, an emc upload, a regional website and a set of educational materials. That is the case for a checklist that walks through every place the old text can survive.
The checklist
Work through the list once per changed section. For each item, record what you found, the decision (update, withdraw or keep), who made it and the date. That record lets you show later what was checked and when.
1. The changed sections
Build the list described above for every changed section: section number, old text, new text, label version and approval date. In the US, include sections outside Recent major changes. In the EU, include every annex the procedure touched, the package leaflet as well as the SmPC. Mark the changes that concern safety, such as a new contraindication, warning or boxed warning, a dose reduction or a new interaction, because those set the pace for everything else on the list. Check the patient leaflet or Medication Guide too, since its changes flow into patient websites and patient support materials.
2. Claims that cite or depend on the changed sections
Start with the claims library and pull every claim whose reference points at a changed section. Then look for claims that depend on a changed section without citing it, such as a population statement that relies on the indication wording or a convenience claim that relies on the dosing. For each claim, decide whether it still holds, needs requalifying or has to be retired. A claim that is still true may need rewording if the label now describes the point differently.
3. References to the superseded version
A reference that records an older label version now points at text that may no longer exist in that form. Update the version on every reference to the label, even where the claim stands, so the next reviewer checks the current text. Where a changed efficacy section (5.1 in an SmPC, Clinical studies in a USPI) now reports a result differently from the publication a claim cites, check the claim against the label, because the label is the agreed position on what the medicine is approved to do.
4. Modules and assets, including reworded and translated copies
Use the where-used view in your content system, for example Veeva PromoMats or Aprimo, to find every module and asset linked to an affected claim. That finds the linked copies. Copies that were never linked, or where the claim was reworded, rounded, translated or set inside an image, need a separate search by meaning across the asset library, including local adaptations in every language. Confirm that each piece carries or links to the current prescribing information.
5. Medical information standard responses
Standard response letters, FAQ documents and contact centre scripts often quote the label directly on dosing, contraindications, interactions and use in specific populations, and they are often managed in a medical information system separate from promotional review. Pull every response for the brand that mentions a changed section, update the label wording and the reference date, and re-approve it. Check responses about unapproved uses too, since a new indication or a new contraindication can change what they need to say.
6. Training and risk minimisation materials
Field training decks, speaker training, onboarding modules and internal FAQs keep teaching the old text until someone replaces them. Risk minimisation materials, the guides, checklists and patient cards that a risk management plan requires, need particular care. In the case above, the updated educational material still had to be submitted to the MHRA for approval, which puts the regulator's review time inside your timeline. Start these as soon as the new text is agreed.
7. Field and congress materials
Printed leave-behinds in stock, content cached on representatives' tablets for offline use, congress booth panels, speaker slide decks and reprint carriers can all outlast a library update. Each needs a written instruction to withdraw, destroy or replace, and a confirmation that it was done. For a safety change, send the field instruction when the change is approved; the case above shows how a routine withdrawal schedule was judged.
8. Public HCP and patient pages
Check brand sites, HCP portals, patient support sites and the prescribing information files they link to. Look at every hosted copy of the PI, SmPC and leaflet, including old file addresses that still open, and pages run by another affiliate or region that local doctors can reach. In the UK case, seven materials related to a regional website without the current prescribing information. Old pages that stay online can keep being found by search engines and read by AI assistants.
9. What AI assistants now answer
The AMA's 2026 physician survey found that 81% of physicians use AI professionally, and summarising medical research and getting updated on standards of care was the most frequently cited use. Ask ChatGPT, Gemini, Perplexity, Claude and Google AI Overviews the questions a doctor would ask about each changed section, for example who should not take the medicine, what dose suits a patient with reduced kidney function, or which combination to avoid. Record each answer, the date and the sources it cites. Where an answer still gives the old information, the cited sources show where it came from, which may be an old page of yours or a third-party page that quoted the old label. Fix the pages you own, log the rest for medical and regulatory review, and ask again a few weeks later. Only public, doctor-style questions need to go to the assistants; none of your internal content does.
10. Agency and market copies
Agencies keep working files, templates and exported copies outside your content system, and local affiliates adapt and translate. Tell each agency and market in writing which claims, modules and assets are changed or retired, and ask for confirmation. Labels move on different dates in different places: a change approved by FDA may reach the EU SmPC later or not at all, and an update to a centrally authorised SmPC reaches each national market's materials through local teams. Check each market against its own label of record.
Who owns each step
Roles differ between companies, so treat this as a starting map and replace the names with your own.
| Step | Usual owner | Works with |
|---|---|---|
| 1. Changed sections | Regulatory affairs or labeling | Medical affairs |
| 2. Claims | Medical affairs, as claims owner | Promotional review (MLR) |
| 3. References | Medical writers | Claims library administrator |
| 4. Modules and assets | Brand and content operations | MLR operations, agencies |
| 5. Standard responses | Medical information | Regulatory, pharmacovigilance |
| 6. Training and risk materials | Training; pharmacovigilance for risk materials | Regulatory, for submission to the agency |
| 7. Field and congress materials | Sales operations and events | Compliance, for withdrawal and destruction |
| 8. Public pages | Digital and omnichannel | Regulatory, for hosted prescribing information |
| 9. AI answers | Medical affairs or omnichannel | Digital, regulatory |
| 10. Agencies and markets | Brand and content operations | Local affiliates, regulatory in each market |
Name one coordinator for the whole change, usually in labeling or promotional compliance, who holds the list, chases each owner and records when each item closed. Without one, each team finishes its own part and nobody checks the gaps between them.
A workable timeline
The UK case report does not set a fixed number of days, and Article 87(2) applies from the date the SmPC changes. The sequence below is a starting point to adapt to your own procedures; shorten it for safety changes.
- When the new text is agreed (the CHMP opinion in the EU, agreed labeling text in the US): build the impact list against the proposed text so withdrawal and revision can start on approval day. EMA's summary of opinion for a contraindication change can be public before the new SmPC is.
- On approval: put a hold on every affected piece. For a safety change, stop use and send field, agency and market instructions the same day. Update the prescribing information your sites host and, in the UK, the emc listing.
- In the first two weeks: brief medical information and the field on the new text, revise and re-approve the most used claims and assets, and submit risk minimisation materials to the regulator.
- In the first month: finish revising claims, modules, assets, standard responses and training. In the US, each revised piece goes to FDA at first use with Form FDA 2253 and the current labeling.
- At one month and again at three months: re-check public pages and AI answers, confirm every withdrawal, and close each item with its evidence.
If your procedures allow six months for a standard update, the case above is worth reading with your compliance team, since that is the window the Panel queried.
How Juncture runs this
Juncture runs this checklist as a Label Change Impact Review with a small number of design partners: one brand, one market and one recent or upcoming label change, run by the Juncture team on the platform beside your normal process. We load the old and new label, from you or from DailyMed, EMA or the emc, split into numbered sections, list what changed, and trace each changed section to the claims linked to it, the references that cite the superseded version, the modules and assets that use those claims (matched by meaning, so reworded and translated copies show up), the medical information letters you share, and what five AI assistants say about it. Each item comes with its evidence and a suggested action, update, withdraw or check, for your reviewers, who make every decision. If you would like to see the outside half on your own brand first, request a Label Change Snapshot: we read the public record of a recent change, check your public HCP and patient pages and the five assistants, and send a short PDF with a 30-minute readout within five business days. You send us nothing. Read more about the review on the label change page.
Sources
- Code of Federal Regulations, 21 CFR 201.57, "Specific requirements on content and format of labeling for human prescription drug and biological products" (paragraphs (a)(5), (a)(15), (c) and (d)(9)). law.cornell.edu
- US Food and Drug Administration, Drug Safety-related Labeling Changes (SrLC) database. accessdata.fda.gov
- National Library of Medicine, DailyMed Labeling Archives. dailymed.nlm.nih.gov
- National Library of Medicine, DailyMed web services (SPL version history). dailymed.nlm.nih.gov
- European Medicines Agency, glossary: European public assessment report. ema.europa.eu
- European Medicines Agency, "What we publish on medicines and when." ema.europa.eu
- European Medicines Agency, example EPAR document: "Procedural steps taken and scientific information after the authorisation." ema.europa.eu
- Datapharm emc support, "What has changed in an updated SmPC or PIL." support.datapharm.com
- emc, Latest medicines updates. medicines.org.uk
- Directive 2001/83/EC, Article 87. legislation.gov.uk
- The Human Medicines Regulations 2012, regulation 280. legislation.gov.uk
- Code of Federal Regulations, 21 CFR 201.100, "Prescription drugs for human use" (paragraph (d)(1)). law.cornell.edu
- Code of Federal Regulations, 21 CFR 314.81, "Other postmarketing reports" (paragraph (b)(3)(i)). law.cornell.edu
- Prescription Medicines Code of Practice Authority, cases AUTH/3041/6/18 and AUTH/3042/6/18, "Updating prescribing information," completed 10 March 2022. pmcpa.org.uk
- American Medical Association, "More than 80% of physicians use AI professionally: AMA survey," 12 March 2026. ama-assn.org